This joint guidance from ECDC and the European Monitoring Centre for Drugs and Drug Addiction provides EU/EEA Member States with evidence-based scientific advice on active case finding options. These options can be applied to the planning and implementation of interventions that promote the early diagnosis of communicable diseases in prison settings.

Most European countries reported no changes in the rate of newly diagnosed cases of HIV or HIV prevalence in IDU in 2011.

This guidance aims to provide EU/EEA countries with an evidence-based framework to help develop, implement, monitor and evaluate their own national HBV, HCV and HIV testing guidelines and programmes.

This guidance is intended for policymakers responsible for the planning and delivery of healthcare services in the national or sub-national custodial system and all professionals responsible for the health and well-being of people in prison, including community-based service providers and those facilitating continuity of care in the community.

This document provides EU/EEA Member States with evidence-based scientific advice on available options, when planning and implementing prevention and control interventions for blood-borne viruses in prison settings.

As the number of people infected with HIV continues to rise, there is increasing evidence that early treatment reduces morbidity and mortality.

As the number of people infected with HIV continues to rise, there is increasing evidence that early treatment reduces morbidity and mortality.

Despite efforts to prevent new HIV infections, more than 27 000 people were newly diagnosed with HIV in the European Union (EU) and the European Economic Area (EEA) in 2010.

Following a request from the European Commission in August 2010, ECDC assessed the epidemiological history of Human T-lymphotropic Virus (HTLV) across the world, possible risks of HTLV transmission through transplantation of human tissues and cells, and possible measures to prevent such transmission.